# A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

> **NCT06672068** · PHASE2 · NOT_YET_RECRUITING · sponsor: **TYK Medicines, Inc** · enrollment: 60 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin
- **DRUG:** TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin

## Key facts

- **NCT ID:** NCT06672068
- **Lead sponsor:** TYK Medicines, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672068, "A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06672068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*